Stereotactic radiotherapy for oligometastatic cancer: a prognostic model for survival.

BACKGROUND Stereotactic radiotherapy (SRT) is a safe and locally effective treatment for patients with inoperable oligometastases. The challenge remains identifying subsets of patients that benefit in terms of overall survival (OS). PATIENTS AND METHODS Between 2005 and 2011, 309 patients with ≤5 metastases were treated by stereotactic body radiotherapy (n=209) and/or by intracranial single or fractionated stereotactic radiotherapy (n=107). We analyzed OS and carried out a risk factor analysis. RESULTS The median survival of all patients was 24 months. The 3-, 4- and 5-year OS rates were 32%, 25% and 19%, respectively. The following four risk factors were independently associated with impaired OS: nonadenocarcinoma histology (P<0.01), intracranial metastases (P<0.01), synchronous oligometastatic disease (P<0.01) and male gender (P=0.02). Patients with 0, 1 and 2 risk factors displayed a median survival (95% CI) of 40 (24-63), 29 (23-35) and 23 (16-29) months, respectively, and are defined as patients with good prognosis. Patients with 3 and 4 risk factors had a median survival of 9 (6-11) and 4 (1-7) months only and are defined as bad prognostic patients. CONCLUSIONS We identified subsets of oligometastatic cancer patients with good prognosis after SRT. These patients are candidates for inclusion in prospective randomized trials for defining the role of SRT in the management of oligometastases.

[1]  A. Allan,et al.  The Role of Cancer Stem Cells in the Organ Tropism of Breast Cancer Metastasis: A Mechanistic Balance between the “Seed” and the “Soil”? , 2011, International journal of breast cancer.

[2]  M. Scorsetti,et al.  Clinical outcome of hypofractionated stereotactic radiotherapy for abdominal lymph node metastases. , 2011, International journal of radiation oncology, biology, physics.

[3]  M. Schell,et al.  A prospective pilot study of curative‐intent stereotactic body radiation therapy in patients with 5 or fewer oligometastatic lesions , 2008, Cancer.

[4]  J. Korbel,et al.  Criteria for Inference of Chromothripsis in Cancer Genomes , 2013, Cell.

[5]  Liljana Mervic.  Time Course and Pattern of Metastasis of Cutaneous Melanoma Differ between Men and Women , 2012, PloS one.

[6]  T. Gupta.  Stereotactic radiosurgery for brain oligometastases: good for some, better for all? , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[7]  H. Lenz,et al.  Influence of sex on the survival of patients with esophageal cancer. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  J. Kao,et al.  Concurrent sunitinib and stereotactic body radiotherapy for patients with oligometastases , 2013, Targeted Oncology.

[9]  B. Neyns,et al.  Phase II study of helical tomotherapy for oligometastatic colorectal cancer. , 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  N. Carter,et al.  Massive Genomic Rearrangement Acquired in a Single Catastrophic Event during Cancer Development , 2011, Cell.

[11]  Samuel Hellman,et al.  Extracranial oligometastases: a subset of metastases curable with stereotactic radiotherapy. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  Phase II study of helical tomotherapy in the multidisciplinary treatment of oligometastatic colorectal cancer , 2012, Radiation oncology.

[13]  L. Gaspar,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for lung metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[14]  Yuman Fong,et al.  Local Surgical, Ablative, and Radiation Treatment of Metastases , 2009, CA: a cancer journal for clinicians.

[15]  M Buyse,et al.  Long-term results of lung metastasectomy: prognostic analyses based on 5206 cases. , 1997, The Journal of thoracic and cardiovascular surgery.

[16]  J. Massagué,et al.  Cancer Metastasis: Building a Framework , 2006, Cell.

[17]  R. Weichselbaum,et al.  Oligometastases revisited , 2011, Nature Reviews Clinical Oncology.

[18]  R. Weichselbaum,et al.  Stereotactic body radiotherapy for multisite extracranial oligometastases , 2012, Cancer.

[19]  L H Blumgart,et al.  Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer: analysis of 1001 consecutive cases. , 1999, Annals of surgery.

[20]  P. Lambin,et al.  Radical Treatment of Non–Small-Cell Lung Cancer Patients with Synchronous Oligometastases: Long-Term Results of a Prospective Phase II Trial (Nct01282450) , 2012, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[21]  Ugo Pastorino,et al.  GENERAL THORACIC SURGERY LONG-TERM RESULTS OF LUNG METASTASECTOMY : PROGNOSTIC ANALYSES BASED ON 5206 CASES The International Registry of Lung Metastases , 2004 .

[22]  H. Lenz,et al.  Gender Disparities in Metastatic Colorectal Cancer Survival , 2009, Clinical Cancer Research.

[23]  W. Franklin,et al.  Multi-institutional phase I/II trial of stereotactic body radiation therapy for liver metastases. , 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[24]  R. K. Jain,et al.  Interstitial fluid pressure in intracranial tumours in patients and in rodents. , 1997, British Journal of Cancer.

[25]  Joe Y. Chang,et al.  Novel Insights of Oligometastases and Oligo-Recurrence and Review of the Literature , 2012, Pulmonary medicine.

[26]  M. Scorsetti,et al.  Review and uses of stereotactic body radiation therapy for oligometastases. , 2012, The oncologist.

[27]  Hemant Ishwaran,et al.  An interferon-related gene signature for DNA damage resistance is a predictive marker for chemotherapy and radiation for breast cancer , 2008, Proceedings of the National Academy of Sciences.

[28]  Merina Ahmed,et al.  Stereotactic body radiotherapy for oligometastases. , 2013, The Lancet. Oncology.

[29]  M. Mehta,et al.  Radiosurgery for patients with brain metastases: a multi-institutional analysis, stratified by the RTOG recursive partitioning analysis method. , 2001, International journal of radiation oncology, biology, physics.

[30]  Y. Fong,et al.  Surgical treatment of colorectal metastases to the liver , 1995, CA: a cancer journal for clinicians.

[31]  A. Altendorf-Hofmann,et al.  Hepatic metastases from colorectal carcinoma: Impact of surgical resection on the natural history , 1990, The British journal of surgery.

[32]  V. Budach,et al.  Oligometastases: the new paradigm and options for radiotherapy , 2013, Strahlentherapie und Onkologie.